The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan

BACKGROUND: Endothelin A receptor antagonists (ET(A)RA) slow chronic kidney disease (CKD) progression but their use is limited due to fluid retention and associated clinical risks. Sodium–glucose co-transporter 2 inhibitors (SGLT2i) cause osmotic diuresis and improve clinical outcomes in CKD and hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Veenit, Vandana, Heerspink, Hiddo J L, Ahlström, Christine, Greasley, Peter J, Skritic, Stanko, van Zuydam, Natalie, Kohan, Donald E, Hansen, Pernille B L, Menzies, Robert I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539223/
https://www.ncbi.nlm.nih.gov/pubmed/37102226
http://dx.doi.org/10.1093/ndt/gfad078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539223/
https://www.ncbi.nlm.nih.gov/pubmed/37102226
http://dx.doi.org/10.1093/ndt/gfad078

Ejemplares similares